Talazoparib plus enzalutamide versus placebo plus enzalutamide in metastatic androgen pathway modulator-resistant (castration-resistant) prostate cancer (TALAPRO-2): a biomarker analysis of circulating tumour DNA and cells for prognosis and molecular profiling
Baseline tumor DNA levels and early clearance during treatment strongly predicted which prostate-cancer patients would benefit from combination therapy.
This exploratory biomarker analysis nested in a randomized double-blind phase 3 trial examined Talazoparib plus enzalutamide versus placebo plus enzalutamide in metastatic androgen pathway modulator-resistant (castration-resistant) prostate cancer (TALAPRO-2): a biomarker analysis of circulating tumour DNA and cells for prognosis and molecular profiling. Baseline ctDNA burden and early ctDNA or circulating-cell clearance were strongly prognostic for radiographic progression-free survival.
What the study was
- Study design
- Exploratory biomarker analysis nested in a randomized double-blind phase 3 trial
- Population
- Men with metastatic androgen-pathway-modulator-resistant prostate cancer
- Sample size
- 805 randomized patients
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- The Lancet. Oncology
Why it surfaced
Exploratory biomarker analysis nested in a randomized double-blind phase 3 trial; Baseline ctDNA burden and early ctDNA or circulating-cell clearance were strongly prognostic for radiographic progression-free survival. Score kept conservative because only the PubMed abstract and metadata were reviewed.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.